Evolving Role of PD-L1 as a Biomarker

Video

For High-Definition, Click

Initial findings from the first reported phase I study looking at nivolumab across multiple tumor types seemed to indicate that PD-1 inhibitors were only effective in PD-L1-positive patients; however, long-term follow-up and data from other trials demonstrated responses in patients with PD-L1-negative disease, Brian I. Rini, MD, notes.

While patients with PD-L1-negative cancer still respond to therapy, it appears that PD-L1-positive patients respond better, Rini notes. However, in studies looking at the combination of the CTLA-4 inhibitor ipilimumab and nivolumab the responses were the same, regardless of PD-L1 expression. As a result, it remains unanswered whether PD-L1 will serve as an effective biomarker in this space.

A variety of definitions and methods for PD-L1 have added to the confusion, Rini notes. Another obstacle to overcome is the definition itself of PD-L1-positivity. At this point, substantial research is still required to fully understand PD-L1 as a biomarker of response.

Related Videos
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Andrew Ip, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Arya Amini, MD
Adrianna Masters, MD, PhD,
Related Content
Lora Markley, Director of Regional Managed Care for The US Oncology Network

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

April 19th 2024
Article
FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

May 2nd 2022
Podcast
Eric S. Christenson, MD, assistant professor, oncology, Johns Hopkins Medicine

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024
Article
Sorting Through Sexism, Guilt, and Motherhood in Medicine

Sorting Through Sexism, Guilt, and Motherhood in Medicine

January 27th 2022
Podcast
Ritu Salani, MD

Clinicians Turn Their Focus to pMMR Disease Following Immunotherapy’s Entrance Into dMMR Endometrial Cancer

April 16th 2024
Article
Matthew Galsky, MD

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

April 16th 2024
Article